Abstract: Provided is a method of treating a bladder cancer in an animal or human comprising: administering to an animal or human patient a therapeutic composition comprising a first fusion protein capable of specifically binding to an epidermal growth factor receptor (EGFR) on the surface of a cancer cell and comprising an epidermal growth factor (EGF) polypeptide conjugated to a bacterial toxin polypeptide and a second fusion protein comprising an anthrax Lethal Factor N-terminus (LFN) conjugated to a Diptheria Toxin A (DTA) catalytic domain.
Type:
Grant
Filed:
May 9, 2017
Date of Patent:
March 17, 2020
Assignee:
Purdue Research Foundation/OTC
Inventors:
Ruben Claudio Aguilar, Timothy L. Ratliff